Zepbound outperforms Ozempic and Wegovy in head-to-head weight loss study
Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, new research suggests.
Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, new research suggests.
The study, published Monday in JAMA Internal Medicine, is thought to be the first head-to-head comparison of the two blockbuster weight loss drugs.
Since Zepbound was approved for weight loss in late 2023, it appeared to have an advantage over Wegovy. Patients taking the highest dose of Zepbound lost around 21% of their body weight over 72 weeks, compared to around 15% for patients on Wegovy after 68 weeks.
But it was difficult to make a direct comparison without a study that looked at both drugs, which are part of a new class of medications called GLP-1s.
“We’ve tracked GLP-1 use over the last year and we’ve seen really dramatic increases, and yet, there’s not a ton of information available on head to head comparisons,” said lead study author Tricia Rodriguez, a principal applied scientist at Truveta Research, a health care data and analytics company.
Rating: 5